217 related articles for article (PubMed ID: 33410766)
1. B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors.
Yuan Z; Gardiner JC; Maggi EC; Huang S; Adem A; Bagdasarov S; Li G; Lee S; Slegowski D; Exarchakis A; Howe JR; Lattime EC; Zang X; Libutti SK
Endocr Relat Cancer; 2021 Feb; 28(2):135-149. PubMed ID: 33410766
[TBL] [Abstract][Full Text] [Related]
2. Structure and cancer immunotherapy of the B7 family member B7x.
Jeon H; Vigdorovich V; Garrett-Thomson SC; Janakiram M; Ramagopal UA; Abadi YM; Lee JS; Scandiuzzi L; Ohaegbulam KC; Chinai JM; Zhao R; Yao Y; Mao Y; Sparano JA; Almo SC; Zang X
Cell Rep; 2014 Nov; 9(3):1089-98. PubMed ID: 25437562
[TBL] [Abstract][Full Text] [Related]
3. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
[No Abstract] [Full Text] [Related]
4. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
[TBL] [Abstract][Full Text] [Related]
5. Host b7x promotes pulmonary metastasis of breast cancer.
Abadi YM; Jeon H; Ohaegbulam KC; Scandiuzzi L; Ghosh K; Hofmeyer KA; Lee JS; Ray A; Gravekamp C; Zang X
J Immunol; 2013 Apr; 190(7):3806-14. PubMed ID: 23455497
[TBL] [Abstract][Full Text] [Related]
6. B7x/B7-H4 modulates the adaptive immune response and ameliorates renal injury in antibody-mediated nephritis.
Pawar RD; Goilav B; Xia Y; Herlitz L; Doerner J; Chalmers S; Ghosh K; Zang X; Putterman C
Clin Exp Immunol; 2015 Feb; 179(2):329-43. PubMed ID: 25205493
[TBL] [Abstract][Full Text] [Related]
7. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.
Zhao R; Chinai JM; Buhl S; Scandiuzzi L; Ray A; Jeon H; Ohaegbulam KC; Ghosh K; Zhao A; Scharff MD; Zang X
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9879-84. PubMed ID: 23716685
[TBL] [Abstract][Full Text] [Related]
8. B7x-from bench to bedside.
Kaur G; Janakiram M
ESMO Open; 2019; 4(5):e000554. PubMed ID: 31555486
[TBL] [Abstract][Full Text] [Related]
9. B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells.
Lee JS; Scandiuzzi L; Ray A; Wei J; Hofmeyer KA; Abadi YM; Loke P; Lin J; Yuan J; Serreze DV; Allison JP; Zang X
J Immunol; 2012 Oct; 189(8):4165-74. PubMed ID: 22972920
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model.
Leung J; St-Onge P; Stagg J; Suh WK
Cancer Immunol Immunother; 2017 Apr; 66(4):491-502. PubMed ID: 28074226
[TBL] [Abstract][Full Text] [Related]
11. Tissue-expressed B7x affects the immune response to and outcome of lethal pulmonary infection.
Hofmeyer KA; Scandiuzzi L; Ghosh K; Pirofski LA; Zang X
J Immunol; 2012 Sep; 189(6):3054-63. PubMed ID: 22855708
[TBL] [Abstract][Full Text] [Related]
12. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome.
Zang X; Thompson RH; Al-Ahmadie HA; Serio AM; Reuter VE; Eastham JA; Scardino PT; Sharma P; Allison JP
Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19458-63. PubMed ID: 18042703
[TBL] [Abstract][Full Text] [Related]
13. A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progression.
Liu Y; John P; Nishitani K; Cui J; Nishimura CD; Christin JR; Couturier N; Ren X; Wei Y; Pulanco MC; Galbo PM; Zhang X; Fu W; Cui W; Bartholdy BA; Zheng D; Lauvau G; Fineberg SA; Oktay MH; Zang X; Guo W
Dev Cell; 2023 Dec; 58(23):2700-2717.e12. PubMed ID: 37963469
[TBL] [Abstract][Full Text] [Related]
14. Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity.
Wei J; Loke P; Zang X; Allison JP
J Exp Med; 2011 Aug; 208(8):1683-94. PubMed ID: 21727190
[TBL] [Abstract][Full Text] [Related]
15. Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model.
Leung J; Suh WK
J Immunol; 2013 Jun; 190(12):6651-61. PubMed ID: 23686485
[TBL] [Abstract][Full Text] [Related]
16. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.
Dangaj D; Lanitis E; Zhao A; Joshi S; Cheng Y; Sandaltzopoulos R; Ra HJ; Danet-Desnoyers G; Powell DJ; Scholler N
Cancer Res; 2013 Aug; 73(15):4820-9. PubMed ID: 23722540
[TBL] [Abstract][Full Text] [Related]
17. The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial.
John P; Wei Y; Liu W; Du M; Guan F; Zang X
Trends Pharmacol Sci; 2019 Nov; 40(11):883-896. PubMed ID: 31677920
[TBL] [Abstract][Full Text] [Related]
18. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8
Li J; Lee Y; Li Y; Jiang Y; Lu H; Zang W; Zhao X; Liu L; Chen Y; Tan H; Yang Z; Zhang MQ; Mak TW; Ni L; Dong C
Immunity; 2018 Apr; 48(4):773-786.e5. PubMed ID: 29625896
[TBL] [Abstract][Full Text] [Related]
19. B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients.
Yao Y; Ye H; Qi Z; Mo L; Yue Q; Baral A; Hoon DSB; Vera JC; Heiss JD; Chen CC; Zhang J; Jin K; Wang Y; Zang X; Mao Y; Zhou L
Clin Cancer Res; 2016 Jun; 22(11):2778-2790. PubMed ID: 27001312
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer.
Li Y; Liu Y; Zhao N; Yang X; Li Y; Zhai F; Zang X; Cui W
Cell Death Dis; 2020 Sep; 11(9):753. PubMed ID: 32934224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
